Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings

ARQT·Reported August 14, 2024·After market close

Arcutis Biotherapeutics, Inc. reported Q2 2024 revenue of $30.9M, beat analyst consensus of $29.1M by $1.8M. Diluted EPS came in at $-0.42, beat the $-0.48 consensus by $0.06.

Revenue

$30.9Mbeat by $1.8M

Consensus: $29.1M

Diluted EPS

$-0.42beat by $0.06

Consensus: $-0.48

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q/A · 0001193125-24-183778

Financial Snapshot

Trailing eight quarters through Q2 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q2 2024 Earnings FAQ

Common questions about Arcutis Biotherapeutics, Inc.'s Q2 2024 earnings report.

Arcutis Biotherapeutics, Inc. (ARQT) reported Q2 2024 earnings on August 14, 2024 after market close.

Arcutis Biotherapeutics, Inc. reported revenue of $30.9M and diluted EPS of $-0.42 for Q2 2024.

Revenue beat the consensus estimate of $29.1M by $1.8M. EPS beat the consensus estimate of $-0.48 by $0.06.

You can read the 10-Q/A periodic report (0001193125-24-183778) directly on SEC EDGAR. The filing index links above go to sec.gov.